159 related articles for article (PubMed ID: 18519723)
1. Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
Koga T; Masuda N; Kakuta M; Namba E; Sugihara C; Fukuoka T
Antimicrob Agents Chemother; 2008 Aug; 52(8):2849-54. PubMed ID: 18519723
[TBL] [Abstract][Full Text] [Related]
2. In vitro postantibiotic effects of tomopenem (CS-023) against Staphylococcus aureus and Pseudomonas aeruginosa.
Tomozawa T; Sugihara C; Kakuta M; Sugihara K; Koga T
J Med Microbiol; 2010 Apr; 59(Pt 4):438-441. PubMed ID: 20093378
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of human-simulated exposures of tomopenem (formerly CS-023) in a murine model of Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus infection.
Sugihara K; Tateda K; Yamamura N; Koga T; Sugihara C; Yamaguchi K
Antimicrob Agents Chemother; 2011 Nov; 55(11):5004-9. PubMed ID: 21844314
[TBL] [Abstract][Full Text] [Related]
4. In vivo pharmacodynamic activity of tomopenem (formerly CS-023) against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus in a murine thigh infection model.
Sugihara K; Sugihara C; Matsushita Y; Yamamura N; Uemori M; Tokumitsu A; Inoue H; Kakuta M; Namba E; Nasu H; Koga T
Antimicrob Agents Chemother; 2010 Dec; 54(12):5298-302. PubMed ID: 20921311
[TBL] [Abstract][Full Text] [Related]
5. In vitro activities of novel trans-3,5-disubstituted pyrrolidinylthio-1beta-methylcarbapenems with potent activities against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
Nagano R; Shibata K; Adachi Y; Imamura H; Hashizume T; Morishima H
Antimicrob Agents Chemother; 2000 Mar; 44(3):489-95. PubMed ID: 10681308
[TBL] [Abstract][Full Text] [Related]
6. In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model.
Morinaga Y; Yanagihara K; Nakamura S; Yamamoto K; Izumikawa K; Seki M; Kakeya H; Yamamoto Y; Yamada Y; Kohno S; Kamihira S
J Antimicrob Chemother; 2008 Dec; 62(6):1326-31. PubMed ID: 18835805
[TBL] [Abstract][Full Text] [Related]
7. Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis.
Chalhoub H; Sáenz Y; Nichols WW; Tulkens PM; Van Bambeke F
Int J Antimicrob Agents; 2018 Nov; 52(5):697-701. PubMed ID: 30081137
[TBL] [Abstract][Full Text] [Related]
8. Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
Koga T; Sugihara C; Kakuta M; Masuda N; Namba E; Fukuoka T
Antimicrob Agents Chemother; 2009 Mar; 53(3):1238-41. PubMed ID: 19104025
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
MacGowan AP; Bowker KE; Noel AR
Antimicrob Agents Chemother; 2008 Apr; 52(4):1401-6. PubMed ID: 18227179
[TBL] [Abstract][Full Text] [Related]
10. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential.
Mushtaq S; Ge Y; Livermore DM
Antimicrob Agents Chemother; 2004 Aug; 48(8):3086-92. PubMed ID: 15273124
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem.
Koga T; Abe T; Inoue H; Takenouchi T; Kitayama A; Yoshida T; Masuda N; Sugihara C; Kakuta M; Nakagawa M; Shibayama T; Matsushita Y; Hirota T; Ohya S; Utsui Y; Fukuoka T; Kuwahara S
Antimicrob Agents Chemother; 2005 Aug; 49(8):3239-50. PubMed ID: 16048932
[TBL] [Abstract][Full Text] [Related]
12. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates.
El Amin N; Giske CG; Jalal S; Keijser B; Kronvall G; Wretlind B
APMIS; 2005 Mar; 113(3):187-96. PubMed ID: 15799762
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity of SM-17466, a novel carbapenem antibiotic with potent activity against methicillin-resistant Staphylococcus aureus.
Sumita Y; Nouda H; Kanazawa K; Fukasawa M
Antimicrob Agents Chemother; 1995 Apr; 39(4):910-6. PubMed ID: 7785994
[TBL] [Abstract][Full Text] [Related]
14. [In vitro antibacterial activities of carbapenems against clinical isolates].
Murase M
Jpn J Antibiot; 1999 Nov; 52(11):667-79. PubMed ID: 10659443
[TBL] [Abstract][Full Text] [Related]
15. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
Hu YF; Liu CP; Wang NY; Shih SC
BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
[TBL] [Abstract][Full Text] [Related]
16. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
Riera E; Cabot G; Mulet X; García-Castillo M; del Campo R; Juan C; Cantón R; Oliver A
J Antimicrob Chemother; 2011 Sep; 66(9):2022-7. PubMed ID: 21653605
[TBL] [Abstract][Full Text] [Related]
17. Alterations of susceptibility of Pseudomonas aeruginosa by overproduction of multidrug efflux systems, MexAB-OprM, MexCD-OprJ, and MexXY/OprM to carbapenems: substrate specificities of the efflux systems.
Okamoto K; Gotoh N; Nishino T
J Infect Chemother; 2002 Dec; 8(4):371-3. PubMed ID: 12525903
[TBL] [Abstract][Full Text] [Related]
18. Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms.
Livermore DM; Yang YJ
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():149-59. PubMed ID: 2553657
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa.
Shibata K; Adachi Y; Kato E; Nagano R; Fuse A; Hashizume T; Ohtake N; Okamoto O; Nakagawa S
J Antibiot (Tokyo); 1997 Feb; 50(2):135-8. PubMed ID: 9099222
[TBL] [Abstract][Full Text] [Related]
20. [The roles of active efflux system overexpression and outer membrane protein OprD deficiency or loss in carbapenem resistance of Pseudomonas aeruginosa].
Yi MY; Wang PY; Huang HJ; Liu YC
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(7):457-62. PubMed ID: 16677571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
